Fucosyllactoses, including 2'-fucosyllactose (2'-FL) and 3-fucosyllactose (3-FL), are important oligosaccharides in human milk that are commonly used as nutritional additives in infant formula due to their biological functions, such as the promotion of bifidobacteria growth, inhibition of pathogen infection, and improvement of immune response. In this study, we developed a synthetic biology approach to promote the efficient biosynthesis of 2'-FL and 3-FL in engineered Escherichia coli. To boost the production of 2'-FL and 3-FL, multiple modular optimization strategies were applied in a plug-and-play manner. First, comparisons of various exogenous α1,2-fucosyltransferase and α1,3-fucosyltransferase candidates, as well as a series of E. coli host strains, demonstrated that futC and futA from Helicobacter pylori using BL21(DE3) as the host strain yielded the highest titers of 2'-FL and 3-FL. Subsequently, both the availability of the lactose acceptor substrate and the intracellular pool of the GDP-L-fucose donor substrate were optimized by inactivating competitive (or repressive) pathways and strengthening acceptor (or donor) availability to achieve overproduction. Moreover, the intracellular redox regeneration pathways were engineered to further enhance the production of 2'-FL and 3-FL. Finally, various culture conditions were optimized to achieve the best performance of 2'-FL and 3-FL biosynthesizing strains. The final concentrations of 2'-FL and 3-FL were 9.12 and 12.43g/L, respectively. This work provides a platform that enables modular construction, optimization and characterization to facilitate the development of FL-producing cell factories.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ymben.2017.03.001 | DOI Listing |
Front Nutr
December 2024
Department of Clinical Laboratory, Dalian Women and Children's Medical Group, Dalian, China.
Background: The interaction between the human breast milk microbiota and human milk oligosaccharides (HMOs) plays a crucial role in the healthy growth and development of infants. We aimed to clarify the link between the breast milk microbiota and HMOs at two stages of lactation.
Methods: The microbiota and HMOs of 20 colostrum samples (C group, 1-5 days postpartum) and 20 mature milk samples (S group, 42 days postpartum) collected from postpartum mothers were analyzed using 16S rRNA gene high-throughput sequencing and high-performance liquid chromatography-tandem mass spectrometry.
Arch Argent Pediatr
December 2024
Instituto de Lactología Industrial (INLAIN, CONICET-UNL), Facultad de Ingeniería Química, Universidad Nacional del Litoral, Santa Fe, Argentina.
Human milk oligosaccharides (HMO) are the specific and selective growth substrate for bifidobacteria, preventing pathogen adhesion, modulating the immune system, and impacting neurodevelopment. Human milk is the best food for the neonate; infant formulas enriched with HMOs are indicated when human milk is not possible or sufficient. HMOs developed and added to available infant formulas are 2'-FL (2'-fucosyl lactose), 3-FL (3-fucosyl lactose), 3'-SL (3'-sialyl lactose), 6'-SL (6'-sialyl lactose), LNT (lacto-N-tetraose), and 3'-GL (3'-galactosyl lactose), the latter being produced in situ by microbial fermentation.
View Article and Find Full Text PDFJ Food Sci
December 2024
Food Microbiology and Function Research Laboratory, Meiji Co., Ltd., Hachioji, Japan.
Human milk oligosaccharides (HMOs) have been positively associated with child neurodevelopment in some cohort studies. However, there is a lack of consistency in the association between HMOs and benefits to infants' brains. Moreover, the quantification methods for HMOs have not yet been standardized.
View Article and Find Full Text PDFJ Nutr
November 2024
Department of Nursing, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China.
Background: Human milk oligosaccharides (HMOs) and other milk-derived metabolites are crucial for infant health, influencing gut microbiota and overall development.
Objective: This study aimed to uncover insights into the variations of HMOs and non-HMO metabolites based on secretor (Se) status, lactation time, mode of delivery, and infant sex.
Methods: An exploratory cross-sectional study was designed to compare the concentrations of HMOs and non-HMOs metabolites in milk samples from 129 lactating Chinese women within 1 y postpartum.
J Agric Food Chem
November 2024
Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China.
This study investigates the relationship among maternal secretor status, human milk oligosaccharides (HMOs), and the composition of breastmilk microbiota in a cohort of healthy mothers from Shaanxi province, China. The results demonstrated that 78.9% of the mothers were secretors, exhibiting an active fucosyltransferase 2 gene () and producing α-1,2 fucosylated HMOs, which significantly affected the HMO profile.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!